Amgen Inc. (NASDAQ: AMGN) Stock Competitors & Peer Comparison
See AMGN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for AMGN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AMGN | $433.73 | -1.95% | 234.1B | 19.39 | $22.37 | +2.26% |
| LLY | $1,244.40 | -2.81% | 1.2T | 39.56 | $31.49 | +0.53% |
| JNJ | $267.37 | -2.21% | 645.3B | 24.96 | $10.73 | +1.95% |
| ABBV | $261.83 | -1.56% | 462.6B | 25.69 | $10.19 | +2.60% |
| MRK | $149.25 | -1.94% | 368.5B | 46.48 | $3.21 | +2.23% |
| NVS | $156.24 | -2.54% | 297B | 17.98 | $8.69 | +3.03% |
| AZN | $164.49 | -0.28% | 255.2B | 17.77 | $9.26 | +1.27% |
| NVO | $46.14 | -0.73% | 205.1B | 11.49 | $4.02 | +2.51% |
| GILD | $143.44 | -2.82% | 178.1B | -367.79 | -$0.39 | +2.22% |
| PFE | $27.79 | -1.59% | 158.5B | 9.12 | $3.05 | +6.15% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
AMGN vs LLY Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, LLY has a market cap of 1.2T. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while LLY trades at $1,244.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas LLY's P/E ratio is 39.56. In terms of profitability, AMGN's ROE is +0.89%, compared to LLY's ROE of +0.93%. Regarding short-term risk, AMGN is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
AMGN vs JNJ Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, JNJ has a market cap of 645.3B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while JNJ trades at $267.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas JNJ's P/E ratio is 24.96. In terms of profitability, AMGN's ROE is +0.89%, compared to JNJ's ROE of +0.26%. Regarding short-term risk, AMGN is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
AMGN vs ABBV Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, ABBV has a market cap of 462.6B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while ABBV trades at $261.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas ABBV's P/E ratio is 25.69. In terms of profitability, AMGN's ROE is +0.89%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, AMGN is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
AMGN vs MRK Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, MRK has a market cap of 368.5B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while MRK trades at $149.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas MRK's P/E ratio is 46.48. In terms of profitability, AMGN's ROE is +0.89%, compared to MRK's ROE of +0.07%. Regarding short-term risk, AMGN is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check MRK's competition here
Novartis AG (NYSE: NVS)
AMGN vs NVS Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, NVS has a market cap of 297B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while NVS trades at $156.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas NVS's P/E ratio is 17.98. In terms of profitability, AMGN's ROE is +0.89%, compared to NVS's ROE of +0.30%. Regarding short-term risk, AMGN is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
AMGN vs AZN Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, AZN has a market cap of 255.2B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while AZN trades at $164.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas AZN's P/E ratio is 17.77. In terms of profitability, AMGN's ROE is +0.89%, compared to AZN's ROE of +0.22%. Regarding short-term risk, AMGN is less volatile compared to AZN. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check AZN's competition here
Novo Nordisk A/S (NYSE: NVO)
AMGN vs NVO Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, NVO has a market cap of 205.1B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while NVO trades at $46.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas NVO's P/E ratio is 11.49. In terms of profitability, AMGN's ROE is +0.89%, compared to NVO's ROE of +0.59%. Regarding short-term risk, AMGN is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
AMGN vs GILD Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, GILD has a market cap of 178.1B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while GILD trades at $143.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas GILD's P/E ratio is -367.79. In terms of profitability, AMGN's ROE is +0.89%, compared to GILD's ROE of -0.16%. Regarding short-term risk, AMGN is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
AMGN vs PFE Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, PFE has a market cap of 158.5B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while PFE trades at $27.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas PFE's P/E ratio is 9.12. In terms of profitability, AMGN's ROE is +0.89%, compared to PFE's ROE of +0.05%. Regarding short-term risk, AMGN is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
AMGN vs BMY Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, BMY has a market cap of 133.8B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while BMY trades at $65.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas BMY's P/E ratio is 11.04. In terms of profitability, AMGN's ROE is +0.89%, compared to BMY's ROE of +0.47%. Regarding short-term risk, AMGN is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check BMY's competition here
Sanofi (NASDAQ: SNY)
AMGN vs SNY Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, SNY has a market cap of 108.4B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while SNY trades at $45.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas SNY's P/E ratio is 9.84. In terms of profitability, AMGN's ROE is +0.89%, compared to SNY's ROE of +0.06%. Regarding short-term risk, AMGN is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check SNY's competition here
GSK plc (NYSE: GSK)
AMGN vs GSK Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, GSK has a market cap of 104.1B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while GSK trades at $51.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas GSK's P/E ratio is 11.22. In terms of profitability, AMGN's ROE is +0.89%, compared to GSK's ROE of +0.24%. Regarding short-term risk, AMGN is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
AMGN vs BIIB Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, BIIB has a market cap of 31.7B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while BIIB trades at $214.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas BIIB's P/E ratio is 13.53. In terms of profitability, AMGN's ROE is +0.89%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, AMGN is less volatile compared to BIIB. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check BIIB's competition here
Zoetis Inc. (NYSE: ZTS)
AMGN vs ZTS Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, ZTS has a market cap of 31.5B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while ZTS trades at $75.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas ZTS's P/E ratio is 11.40. In terms of profitability, AMGN's ROE is +0.89%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, AMGN is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check ZTS's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
AMGN vs HZNP Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas HZNP's P/E ratio is 61.86. In terms of profitability, AMGN's ROE is +0.89%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, AMGN is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
AMGN vs GRFS Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while GRFS trades at $7.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas GRFS's P/E ratio is 9.18. In terms of profitability, AMGN's ROE is +0.89%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, AMGN is less volatile compared to GRFS. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
AMGN vs OGN Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while OGN trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas OGN's P/E ratio is 4.10. In terms of profitability, AMGN's ROE is +0.89%, compared to OGN's ROE of +0.23%. Regarding short-term risk, AMGN is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for AMGN.Check OGN's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
AMGN vs CELG-RI Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, CELG-RI has a market cap of 208.4M. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while CELG-RI trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, AMGN's ROE is +0.89%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, AMGN is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check CELG-RI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
AMGN vs CTOR Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, CTOR has a market cap of 70.6M. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while CTOR trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas CTOR's P/E ratio is -1.62. In terms of profitability, AMGN's ROE is +0.89%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, AMGN is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check CTOR's competition here
Scilex Holding Company (NASDAQ: SCLX)
AMGN vs SCLX Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, SCLX has a market cap of 49.2M. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while SCLX trades at $5.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas SCLX's P/E ratio is -0.15. In terms of profitability, AMGN's ROE is +0.89%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, AMGN is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
AMGN vs SCLXW Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, SCLXW has a market cap of 44.7M. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while SCLXW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas SCLXW's P/E ratio is N/A. In terms of profitability, AMGN's ROE is +0.89%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, AMGN is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check SCLXW's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
AMGN vs MIRA Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, MIRA has a market cap of 29.8M. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while MIRA trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas MIRA's P/E ratio is -0.49. In terms of profitability, AMGN's ROE is +0.89%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, AMGN is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check MIRA's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
AMGN vs CRXT Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas CRXT's P/E ratio is -0.02. In terms of profitability, AMGN's ROE is +0.89%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, AMGN is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check CRXT's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
AMGN vs BDSIW Comparison August 2026
Amgen Inc. (NASDAQ: AMGN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AMGN stands at 234.1B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, AMGN is priced at $433.73 on the NASDAQ, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AMGN currently has a P/E ratio of 19.39, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, AMGN's ROE is +0.89%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, AMGN is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for AMGN.Check BDSIW's competition here